India unveils world's first nasal vaccine for Covid (Photo for representation)
The booster dose of Bharat Biotech’s Covid-19 nasal vaccine iNCOVACC was given emergency use authorisation (EUA) by the Drugs Controller General of India (DCGI).
The EUA is reported to have been granted for restricted emergency use as the third dose for adults irrespective of having been administered Covaxin or Covishield vaccine doses.
According to the Hyderabad-based vaccine manufacturer, the nasal route has excellent potential for vaccination due to the organised immune systems of the nasal mucosa.
iNCOVACC is India’s first nasal vaccine developed against Covid-19. The nasal vaccine can be taken after six months of the second dose. As this is non-invasive and needle-free, it becomes easy to administer.
The intranasal immunisation of ChAd-SARS-CoV-2-S can create an immune response in the nose, which is the point of entry for the virus. The booster dose will thereby protect against disease, infection, and transmission.
Jamil Maqsood, the President of the Foreign Affairs Committee of the United Kashmir People's National…
The 6th meeting of the ASEAN-India Trade in Goods Agreement (AITIGA) Joint Committee concluded in…
The US Department of Homeland Security (DHS), on behalf of the Forced Labor Enforcement Task…
A delegation from the Tibetan Parliament-in-Exile (TPiE), led by Speaker Khenpo Sonam Tenphel and accompanied…
On the sidelines of the 2nd India-CARICOM Summit, leaders of the member countries witnessed a…
India's economic growth story has witnessed a remarkable surge in investment spending, with over half…